 SAN DIEGO, Oct. 13, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento previously announced that its partner Escugen Biotechnology Co, Ltd. Escugen and Sorrentos subsidiary Levena Suzhou Biopharma Co., Ltd. Levena had received an approval letter from the Center for Drug Evaluation CDE of the National Medical Products Administration NMPA for its Application for Clinical Trial Acceptance No. CXSL2101069 of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate. Today Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors. 